Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Histopathology

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/his.12809PMID 26272590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer

  2015cited by this paper
• BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas

  2013cited by this paper
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013cited by this paper
• Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours

  2013cited by this paper
• The role of BRCA1 and BRCA2 in prostate cancer.

  2012influential reference
• BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection.

  2011cited by this paper
• Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

  2009cited by this paper
• Overexpression of RAD51 occurs in aggressive prostatic cancer

  2009influential reference
• Multiple loci on 8q24 associated with prostate cancer susceptibility

  2009cited by this paper
• Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

  2008cited by this paper
• Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma

  2007cited by this paper
• Inexpensive and precise paraffin tissue microarrays constructed with a computer numerical control (CNC) drilling machine

  2007cited by this paper
• Prostate cancer progression and survival in BRCA2 mutation carriers.

  2007cited by this paper
• Cellular functions of the BRCA tumour-suppressor proteins.

  2006cited by this paper
• The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

  2006cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006influential reference
• Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.

  2006cited by this paper
• High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

  2005cited by this paper
• Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

  2003cited by this paper
• Cancer susceptibility and the functions of BRCA1 and BRCA2.

  2002cited by this paper
• Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2

  2002cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer

  2000influential reference
• In search of the tumour-suppressor functions of BRCA1 and BRCA2

  2000cited by this paper
• Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium

  1999cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.

  1997influential reference
• Tissue- and species-specific antigens of normal human prostatic tissue.

  1970cited by this paper

• Decoding the Transcriptional Complexity of the Human BRCA2 DNA Repair Gene Using Hybrid-seq.

  2025cites this paper
• Comparison of molecular analysis results determined by next-generation sequencing to immunohistochemical indicators and clinicopathological parameters in prostate adenocarcinomas.

  2024cites this paper
• Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer

  2022cites this paper
• Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer

  2022cites this paper
• Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

  2021cites this paper
• TP53 alterations of hormone-naïve prostate cancer in the Chinese population

  2020cites this paper
• Neoplasms of the Prostate

  2020cites this paper
• The Prostate

  2019cites this paper
• BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.

  2018cites this paper
• BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer

  2017cites this paper
• Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer

  2016cites this paper